Closed brianmackenna closed 2 years ago
Brian, the atopic eczema Read codes are . at, https://datacompass.lshtm.ac.uk/1281/1/readcodes-eczemaDx-exca.txt. The treatment codes are at https://datacompass.lshtm.ac.uk/1254/1/final_prodcodes-eczemaRx.txt. The algorithm is based on a record of one diagnostic morbidity code (recorded in either primary or secondary care) and at least two records (on separate days) for eczema therapy (recorded in primary care using Read morbidity codes or prescription data). Eczema therapy included primary care records of (1) morbidity codes for phototherapy and (2) prescriptions for topical emollients, corticosteroids or calcineurin inhibitors, or oral glucocorticoids, azathioprine, methotrexate, ciclosporin or mycophenolate. We identified phototherapy using Read codes in primary care and Office of Population Censuses and Surveys (OPCS) procedure codes in secondary care. Systemic eczema treatment was identified using primary care prescription records. Hospital admissions for eczema were identified as any hospitalisation in which an ICD-10 code for eczema was recorded in the primary diagnostic position of any episode associated with the hospitalization. Reference here in supplementary 3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315391/
Phototherapy codes are here: https://datacompass.lshtm.ac.uk/1282/1/readcodes-eczemaRx-exca.txt
Great. We'll get these mapped to snomed/dm+d. A few questions
1) Are there date limits on the algorithm e.g. is it eczema code ever
or last 12 months
?
2) Oral medicines: These are used for a wide variety of conditions and generally in eczema they are only used in severe disease. I'm thinking they may add to false positives for eczema and the topical may be sufficient? Some of the things in the list (e.g. dexamethasone solution) are unlikely to be used for eczema I think ? Should we restrict to just topicals?
Or maybe there's a validation study I haven't seen yet?
There is, it's at https://pubmed.ncbi.nlm.nih.gov/28428130/. For eczema, code in last three years with two treatments would be best. Won't identify "ever eczema" but will identify "active eczema". Agree Dexamethasone solution unlikely to be used for eczema- would remove.
DEFINITION: Atopic Eczema Snomed list
CODE LISTS: mark-yates-atopic-eczema-2020-10-21T16-19-11.xlsx
This was created , through the following strategy: Code builder
FLEXIBILITY NEEDED BETWEEN STUDIES: Nil
EFFECTS ON COHORT SELECTION: Needs combining with drug list
POTENTIAL BIASES: This list is much more expanded than the LSHTM above, let me know if this is incorrect.
CLINICAL SIGN OFF & DATE: Needs checking by @sinlangan
EPIDEMIOLOGY SIGN OFF & DATE: Do you mind having a look @katetheyogi
SHARED WITH WIDER TEAM:
FINAL SIGN OFF DATE (and apply label):
@myatesrheum and @brianmackenna, the morbidity code variable seems to have become corrupted. I have highlighted codes I don't think should be included in yellow. How does eczema NOS map across?
The original Read codes are in, readcode_eczema.docx and the edited code list at, mark-yates-atopic-eczema-2020-10-21T16-19-11_sml.xlsx
I have had a quick look and the majority of exclusions from @sinlangan appear to be related to "contact dermatitis". @myatesrheum I can't edit your codelist directly but if you look for "parent" like in image below it will exclude large groups related to "contact dermatitis" without having to go through each code individually.
To be developed. Guidance on codelists development is available here in documentation folder.
The following template should be completed the first time a codelist is developed and uploaded to https://codelists.opensafely.org/
DEFINITION:
CODE LISTS: Upload excel file here
This was created , through the following strategy:
FLEXIBILITY NEEDED BETWEEN STUDIES:
EFFECTS ON COHORT SELECTION: POTENTIAL BIASES:
CLINICAL SIGN OFF & DATE:
EPIDEMIOLOGY SIGN OFF & DATE:
SHARED WITH WIDER TEAM:
FINAL SIGN OFF DATE (and apply label):